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Novel ligands BQ123 and BQ3020 characterize endothelin
receptor subtypes ETA and ETB in human kidney
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Novel ligands BQ123 and BQ3020 characterize endothelin receptor
subtypes ETA and ETB in human kidney. Endothelins (ET), a group of
vasoconstrictor peptides, are expressed in a wide range of tissues and
species and bind to specific receptors of which there are at least two
subtypes, ETA and ETB. The kidney has been found in animal studies
to be highly sensitive to the effects of ET. We have used two new
peptide ligands, which are selective for particular ET receptor subtypes
(the antagonist BQ123 for ETA and the agonist BQ3020 for ETB) in
binding studies to characterize human renal ET receptors. Saturation
studies gave equilibrium dissociation constants (l(d) for [V25IET-1 of
0.17 0.04 nM and for [V25]BQ3020 of 0.36 0.06 nM. Hill coefficients
were 0.86 0.03 and 0.77 0.04, respectively. Macro- and microau-
toradiography using [P25]-labeled ligands with BQ123 and BQ3020 as
competing blockers showed the majority of ET binding to be in the
medulla with concentration in the vasa recta bundles, and ETA binding
localizing to vascular smooth muscle. The ET subtype predominated
over ETA receptors by about 2:1, and was more generally distributed,
with concentration in the collecting system. These findings were
confirmed by competition binding assays giving Bmax values (ETa/ETA,
fmol/mg protein), for medulla and cortex, respectively, of 18.7
2.2/11.3 2.7and 12.7 3.9/7.6 3.5forBQ3O2O;and36.2 5.6/11.1
4.1 and 14.9 1.6/5.3 0.2 for BQ123. This study establishes ETA
and ET receptor distribution in human kidney and demonstrates that
the novel ligands BQ123 and BQ3020 have at least thousand-fold
selectivities for the ETA- and ETB-receptor subtypes, respectively. The
results show that, in contrast with other human tissues such as heart,
kidney contains predominantly the ET subtype.
The endothelins (ET) are a group of powerful vasoconstrictor
peptides, first isolated in 1988 [1], for which a clear physiolog-
ical role has yet to be identified. Three isoforms (ET-1, ET-2,
ET-3) have been predicted to exist from studies of cDNA
libraries isolated from several species [2]. ET-1 is thought to be
the most widely distributed. The kidney has been shown to be
very sensitive to the effects of low concentrations of exogenous
ET-1; in animals, intact and isolated perfused organs exhibit
rises in renal arterial and afferent and efferent arteriolar pres-
sure [3], and falls in plasma flow, glomerular filtration rate and
urine production [4, 5]. Cultured mammalian mesangial cells
(which are thought to be of smooth muscle origin) contract [6,
7], and cell growth and division are stimulated [4, 8]. High
affinity receptors for ET- 1 have been demonstrated in studies of
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renally derived cultured cells from several species [9, 10], but
how these findings relate to the in vivo kidney is not known.
Cultured mesangial cells synthesize ET [11], suggesting a
possible autocrine or paracrine role. Autoradiographic studies
show variations in ET receptor distribution between species,
with a high density of ET- 1 binding in rat glomeruli compared
with pig and human [12—15], though not all authors agree. This
anatomical variation is of interest in terms of possible interspe-
cies functional differences, and highlights the need to charac-
terize endothelin receptor subtypes in human renal tissue for
the elucidation of the potential pathophysiological effects of
these peptides in humans.
Earlier studies in a variety of tissues and species have
identified the existence of at least two endothelin receptor
subtypes; at present two have been isolated and cloned, desig-
nated ETA and ET8 [reviewed in 16]. Several studies have now
begun to characterize these subtypes in different non-renal
tissues, for example the human heart contains predominantly
the ETA-subtype [17]. Recent studies of preparations of ex-
tracted renal material suggest that there may be a greater
proportion of ETB in human than in rat kidney cortex [18, 19].
However, little is known of the regional localization of the two
subtypes in any mammal.
Recently, compounds selective for a single receptor subtype
have been developed. These are BQ123 (cyclo[D-Asp-L-Pro-D-
Val-L-Leu-D-Trp-]) which is selective for ETA [20], and
BQ3020 ([Ala"5]Ac-ET-1(21)), thought to be ETB-selective
and which has also been studied in human tissue [17, 21—23].
The development of these compounds now allows a more
detailed study of ET receptors. In order further to delineate
endothelin binding and receptor subtype characteristics in the
human kidney, we have used BQ123 and BQ3020 in combina-
tion with radiolabeled ET- 1 in in vitro receptor binding assays
and quantitative autoradiographic studies.
Methods
Kidney tissue
Normal kidney specimens were obtained at the time of
nephrectomy from three male adults with tumors (Table 1),
immediately frozen in liquid nitrogen, and stored at —70°C.
Cross sectional segments were mounted in O.C.T. compound
and uniform 10 m sections were cut on a cryostat and
thaw-mounted on gelatin/chromic potassium sulphate-coated
slides. Light microscopy of hematoxylin and eosin stained
sections confirmed the presence of normal glomerular and
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Table 1. Nephrectomy patient details
Patient 1 Patient 2 Patient 3
Sex Male Male Male
Age years 48 55 61
Smoker? Yes No No
Diagnosis
Principal Pheochromocytoma Hypernephroma Hypernephroma
Others None Asthma, OA Asthma
Drugs Phenoxybenzamine
Diclofenac sodium
Salbutamol inhaler
Beclomethasone inhaler
Tiprofenic acid
Salbutamol inhaler
Beclomethasone inhaler
Prothiaden
BP mm Hg 150/95 120/80 130/80
Urea mmo!/liter 3.3 6.0 4.4
Creatinine imo1/liter 92 134 95
Blood group A+ A+ 0+
Competition binding assays
tubular structures. Comparison was also made with sections
stained with an anti-von Willebrand factor antibody (Dako Ltd.,
High Wycombe, Bucks, UK).
Ligands
BQ 123 (cyclo[D-Asp-L-Pro-D-Val-L-Leu-D-Trp-]) was syn-
thesized by Dr. A. Doherty, (Parke-Davis Pharmaceutical Di-
vision, Ann Arbor, Michigan, USA) using solid phase t-boc
chemistry and purified by gel filtration. The sequence was
confirmed by amino acid analysis. Absence of reaction with
ninhydrin reagent indicated that successful cyclization had been
achieved. The linear analogue showed no detectable inhibition
of radioiodinated ET- 1 binding to vascular smooth muscle cells
in culture. BQ3020 ([Ala' "15]Ac-ET-1(2,)) was synthesized in
house using similar methods. It did not show any detectable
binding to cultured A10 rat aortic vascular smooth muscle cells,
which express only ETA mRNA [17]. Peptide concentrations
were determined by ultraviolet spectrophotometry in both
cases. Amino acid sequences are shown in Figure 1.
Saturation experiments
Under the assay conditions previously described by Daven-
port et al [21], consecutive 10 sm sections of medulla were
preincubated for 15 minutes at 20°C in 500 p1 of buffer (pH 7.4)
containing 50 mi HEPES, 5 mri MgCI2, and 0.3% bovine
serum albumin (Advanced Protein Products Ltd., Brierley Hill,
West Midlands, UK). Thereafter they were incubated for
two hours in 200 p1 of the same buffer containing increasing con-
centrations of either (3-['251]iodotyrosyl'3)ET-l or [I'25]BQ3020
(Amersham International p.l.c., Amersham, Bucks., UK) in the
range 0.01 to 8 nM. Non-specific binding was determined using
alternate sections in the presence of an excess concentration
(106 M) of either unlabeled ET-l (Novabiochem p.l.c., Not-
tingham, UK) or BQ3020. The slides were washed three times
in ice-cold 50 mM-Tris-HC1 buffer and the sections wiped onto
glass-fiber papers. The amount of radioactivity was measured in
a gamma counter. The specific activity of both radiolabeled
compounds was 2000 Cilmmol. Binding parameters and the Hill
coefficient (nH) were calculated by Scatchard analysis of curves
generated by EBDA [24]. The equilibrium constant (KD) and
maximum receptor density (Bmax) were derived by iterative
non-linear curve fitting using LIGAND [25], the latter values
being expressed as fmol/mg protein.
Under the same assay conditions, cortex and medulla sec-
tions were incubated with 250 p1 of 100 M [I'25]ET-l and in a
dose-dependent manner with either unlabeled BQ123, or
BQ3020, in the range 10 to l012 M. Non-specific binding was
again determined using 106 M unlabeled ET- 1. The data were
analyzed using EBDA and LIGAND. The ratios of receptor
subtypes present were calculated by comparison of the Bmax
values for ETA and ETB.
Protein assay
Ten micrometer sections cut at the same time as for the above
experiments were solubilized in buffer containing 0.5 M NaOH
and 1% SDS, at 80°C for 30 minutes. After centrifugation at
11000 rpm for five minutes, the supernatants were removed and
the protein content assayed using a modified Lowry microtiter
plate protein assay (BioRad DC, Richmond, California, USA).
Bovine serum albumin, at concentrations of 0.18 to 1.5 mg/ml,
was used to obtain standard curves.
Receptor macroautoradiography
This technique has been previously described in detail [26].
Briefly, duplicate 10 sm sections were preincubated as above.
They were then incubated with 400 p1 of b_b M [I'25]ET-l
either alone or with one of the following: 106 M unlabeled
ET-1; 2 x l0 M BQ3020; or l0 BQ123. Similar sections
were incubated with [I'25]BQ3020 alone or in combination with
unlabeled BQ3020. As previously described [17], the concen-
trations of competing ligands were chosen by application of the
mass action equation, such that BQ3020 selectively blocked the
ETB subtype with less than 0.4% binding to ETA receptors,
while BQ123 selectively blocked ETA with less than 5% ETB
binding. The slides were washed as above, dried in a cold air
stream for at least 30 minutes, and apposed to radiation
sensitive film (Hyperfilm-f3max, Amersham) for a minimum of
three days. The films were developed using standard methods.
Computerized densitometry and comparison with [1125]-stan-
dards [27] were used to produce color-coded images and to
determine the amount of bound radioactivity, which was ex-
pressed as amol/mm2. From these data, the relative densities of
ETA and ETB were calculated. Comparative sections were
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stained with either hematoxylin and eosin or antibody to von
Willebrand factor using standard methods [27].
Receptor microautoradiography
As previously described [28], 10 m sections were thaw-
mounted and fixed by heating with paraformaldehyde in a
sealed container for one hour at 80°C. Thereafter they were
treated as above until dried. The slides were then immersed at
43°C in a mixture of KS photographic nuclear emulsion (Ilford
Ltd., Knutsford, UK) and glycerol for 5 seconds, chilled and
dried, and stored at 4°C for two weeks. They were then
developed using standard methods and the developed silver
grains visualized by light microscopy. The underlying tissues
were counterstained with hemalum for structural comparison.
Results
In saturation studies, [I'25]ET-1 bound with high affinity to
medulla over the concentration range 0.01 to 8 nM, as shown in
Table 2, and with similar affinity in cortex. Hill coefficients were
less than unity; however, a one-site model was preferred by
LIGAND in each assay. The data were analyzed for one, two
and three site fit, both individually and by pooling data files.
Selection of best fit was by F-ratio testing to the P < 0.05
significance level. Re-analysis of the data in the concentration
range 0.01 to 1 n yielded the expected coefficient of 1.0
0.04. [I'25]BQ3020 also gave sub-nanomolar KD values with
slightly lower affinity and similar Hill slopes. Again a one-site
Parameter {I'25]ET-1 [I'25]BQ3020
Kd flM 0.17 0.04 0.36 0.06
Bxfmol/mg protein 57.7 15.4 30.0 5.0
nH 0.86 0.03 0.77 0.04
model was preferred. The maximum receptor density obtained
from these saturation studies was 48% lower for {I'251BQ3020
than for [I'25}ET-l (30.0 5.0 fmol/mg compared with 57.7
15.4 fmollmg).
Data from competition experiments are summarised in Tables
3 and 4. The ETA-selective BQ123 competed for the binding of
[I'25]ET-l in both medulla and cortex. Pseudo-Hill slopes were
less than unity and LIGAND selected a two-site fit in prefer-
ence to either a one- or a three-site model. A representative
pooled competition curve (Fig. 2) shows the expected gradient
changes for the two receptor subtypes. BQ123 displayed about
2800-fold selectivity for ETA in medulla and 250-fold selectivity
in cortex in these kidneys. Calculated Bmax values showed that
68% and 71% of total ETA and ETB, respectively, were in
medulla. In comparison, BQ3020 was about 1700-fold and
400-fold selective for ETB in medulla and cortex, respectively,
and showed 60% of total ETA and ET to be in medulla.
Autoradiographical studies confirmed that both ETA and ETB
C
Ac
c Fig. 1. Amino acid sequences of(a) ET-J; (b)
ETA-selective ligand BQ123; (c) ETB-selective
ligand BQ3020. D-isomers indicated by
11 15 21 asterisks; Ac = acetyl.
Table 2. Saturation data for [I'25]ET-l binding to human renal
medulla (N = 3; mean SEM)
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Parameter Medulla Cortex
Kd
ETpM 5.0± 1.3 2.07±0.8
ETB nM 3.0 1.4 4.87 1.4
B max
ETA fmollmg 11.3 2.7 7.6 3.5
ETf,no!/mg 18.7 2.2 12.7 3.9
ETB:ETA % 63:37 63:37
Parameter Medulla Cortex
Kd
ETA nM 11.8 4.0 26.0 15.0
ETB ;LM 32.8 8.0 6.5 2.2
B max
ETAfmol/mg 11.1 4.1 5.3 0.2
ETBfmoI/mg 36.2 5.6 14.9 1.6
ETB:ETA % 76:24 74:26
subtypes were found throughout renal tissue. The macroauto-
radiographic distribution of [1125]ET-1 binding is shown in
Figure 3, a longitudinal section with cortex uppermost. In the
upper panels are shown total and non-specific binding. In the
lower left panel, blocking of ETB with unlabeled BQ3020
reveals the distribution of ETA, while on the right ETA has been
blocked with BQ123, thus showing ETB binding. In the cortex
binding was more marked in association with small blood
vessels, but was not discretely seen within glomeruli. ETB
predominated, but ETA was more discretely localized to ves-
sels, as seen in the inset to Figure 3. The majority of binding,
however, was concentrated in the medulla, especially in the
medullary rays, and ETB again predominated. For more de-
tailed localization, Figure 4 shows representative microautora-
diographs; results with this technique confirmed that vascular
medial tissue has a high proportion of ETA receptors. Figure 4A
demonstrates the high density of silver grains in the nuclear
emulsion overlying an arteriole in conjunction with the faintly
stained glomerulus below. Concentration of silver grains can be
seen at the vascular pole of the glomerulus, but not within the
glomerulus itself. This distribution was not seen for the ETB
subtype, where binding was more generalized and was most
dense on nonvascular structures, particularly in the tubules and
collecting ducts. In Figure 4B, where silver grains correspond
to the ETB subtype, the central area contains a larger vessel
over which there was no increase in silver grain density over
background levels, indicating an absence of detectable ETB
receptors. The tubules are clearly delineated in comparison.
Table 5 shows the results of computer-assisted image analysis
of receptor-bound radioactivity for each receptor subtype from
the macroautoradiographs, ETB accounting for about 65% of
total specific binding.
Discussion
We have established that both the nonselective radioligand
[I'25]ET-l and the novel ETB-selective radioligand [1125}BQ3020
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Fig. 2. Competition curve for inhibition of[1'25]ET-1 binding by unla-
beled BQ3020 in cortex (N = 3; mean reM).
bind to human kidney with high affinity, the latter not having
been thus employed before. The saturation studies showed the
affinity of ET-l binding to receptors to be in the i0'° M range,
which is similar to data from other tissues and species in several
reports including human cardiovascular tissue [21], but is higher
than in a single previous human renal report which had sug-
gested 108 M range affinity of [I'251ET-l in homogenates [14].
The maximum receptor density was in the l0 ' mollmg protein
range, and as expected from autoradiographic analysis, was
about twice as high in medulla as in cortex. The results with the
ETB-selective [I'25]BQ3020 were similar, with a slightly lower
density of binding, as expected. These findings show the human
kidney to be an ET-rich tissue, which is in contrast to other
human tissues, for example from the cardiovascular system
[17]. Over the concentration range used here, the Hill coeffi-
cients for both ligands were always less than unity, which raises
the possibility that ET binds to a heterogeneous receptor
subtype population. However, on no occasion did LIGAND
prefer a two-site fit (P < 0.05); thus, the affinity for any other
receptor would be likely to below. Re-analysis of the data in the
concentration range 0.01 to 1 n yielded coefficients close to 1
as seen in other reports, and similar observations have been
made in human cardiac tissue [211.
These studies use, for the first time, novel ETA- and ET8-
selective ligands to describe binding characteristics of ET-l in
the histologically normal adult human kidney. Both ETA and
ETB receptors were widespread in the renal parenchyma. The
fractional distribution of receptors demonstrated autoradio-
graphically, with about two-thirds of total binding in the me-
dulla, is confirmed by the competition binding data. In the
Table 3. Competition binding assay results using [I'25]ET-1 with 120
BQ3020 (N = 3; mean 5EM)
Table 4. Competition binding assay results using [I'25}ET-1 with
BQ123 (N = 3; mean SEM)
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FIg. 3. Autoradiographic image (x3), of longitudinal kidney sections with cortex uppermost, showing [1125JET-1 binding: T, total binding; NSB,
non-specific binding; ETA, binding to ETA receptors revealed by blocking TB with B03020, (inset shows blood vessel outlined by ETA-bound
[I'251ET-l) ETB, binding to El'8 receptors revealed by blocking ETA with BQ123, discrete binding to vascular structures is not seen. Distinct
glomerular binding is not seen for either receptor subtype.
cortex the relatively fewer binding sites are localized, for the
ETA subtype, to vascular media (as seen in the lower panel
inset to Fig. 3 and in Fig. 4A). This is not seen for ET8
receptors when compared with hematoxylin and eosin stained
parallel sections, and as shown by comparison of the two lower
panels in Figure 3. ET binding was much more heterogeneous.
These impressions were confirmed by the light microscopic
analysis of sections dipped into autoradiographic emulsion (as
in Fig. 4). We did not find any higher density of receptors in the
glomeruli compared with surrounding structures, which is in
accord with a previous report [121, and differing from that seen
in rat [29]. ET8 binding is more concentrated in the medulla,
particularly in medullary rays. It has previously been suggested
in studies of other tissue that ETA receptors are present on
vascular smooth muscle cells, with the ETB subtype on endo-
thelial or epithelial cells, and thus may mediate different func-
tions [16]. The high density of ET binding seen in the medulla
may reflect this. For example, these receptors may be involved
in clearing ET from the circulation, or in altering salt and water
balance through inhibition of Na/K-ATPase, as has been
found in rabbit collecting duct epithelial cells [301, and more
recently in cultured rat cells where ET-l stimulated pros-
taglandin E2 production [311. The prevalence of ETB over ETA,
by a factor of about two, may also reflect functional differences.
We were unable at light microscope level to detect ETB binding
localized to the endothelium. Studies at the electron micro-
scope level will be required to confirm the cellular localization
of ETB receptors in the medulla, but our studies are strongly
suggestive that the ETB subtype is in fact at least partly
epithelially expressed.
The competition assays using these ligands confirm that
BQ123 and BQ3020 are selective for ETA and ETB, respec-
tively, with at least a thousand-fold higher affinity for the
selected receptor subtype in each case. The dissociation con-
stants derived from competition binding assays and saturation
data differed by a factor of 10, which may be due to differing
receptor-ligand conformation between labeled and unlabeled
compounds. BQ123 has been shown to function as an antago-
nist [20], whereas BQ3020 is thought to be an agonist [32]. This
difference may explain the slight inequality in the relative
abundance of the two receptor subtypes calculated from com-
petition data.
B'
'I;
-
- S
- :- -
—
-p
' '! —. •
-—
-
p 'ha;. r •.
-, '%*#' a
•
- ••s -0' - -5,
-e1
4
• I.?
-0' 4 .,' —.
• r.
&ri_
4 1
V
1
P
Karet et al: New ligands and ET receptor subtypes 41
Fig. 4. Bright field photomicrographs showing the microautoradiographic distribution of (A) ETA and (B) ETB receptors in two kidney cortex
sections. Receptors are visualized as the pattern of silver grains in nuclear emulsion overlying tissue sections previously incubated with [I'25]ET-1
and either BQ3020 (A) or BQ123 (B). A. High density of silver grains delineate a vessel (arrowed V) in association with a glomerulus, outlined by
arrows. Discrete binding is not seen within the glomerulus. B. The central blood vessel (V) shows no discrete binding compared with background
levels, whereas tubules show a high binding density. Scale bar = 100 m.
Table 5. Computerized densitometric analysis of autoradiograms
Total ETA ETB ETB:ETA %
Cortex 14.7 1.8 6.0 1.1 10.8 1.0 64:36
Medulla 35.4 4.7 14.5 3.1 27.4 3.8 65:35
Values in amol/mm2 represent means of at least three readings in each
of three tissues.
The selectivities of BQ123 and BQ3020 demonstrated here,
together with their proposed antagonist or agonist properties,
and the finding that the human kidney expresses predominantly
ET8 receptors, will allow further studies of receptor subtype
localization at the cellular level, and selection of appropriate
models for investigation of the possible functional role of
endothelin in the kidney.
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